Lymphoma — cancer of the lymphatic system — includes both Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL). These are meaningfully different diseases with different treatment protocols, prognoses, and medical aid coverage realities. This article covers both, with a focus on what South African medical aid members need to understand about PMB obligations, rituximab access, and the cost of modern lymphoma treatment.
What Is Lymphoma?
The lymphatic system is a network of nodes, vessels, and organs (including the spleen, thymus, and bone marrow) that is part of the immune system. Lymphoma arises when lymphocytes (white blood cells) grow abnormally.
Hodgkin Lymphoma (HL): Characterised by the presence of Reed-Sternberg cells on biopsy. It typically affects younger adults (bimodal peaks at ages 20–29 and 65+). Highly treatable with ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) — cure rates exceed 80–90% in early-stage disease. SA patients have good access to ABVD as a cost-effective regimen.
Non-Hodgkin Lymphoma (NHL): A heterogeneous group of over 60 lymphoma subtypes. The most clinically significant in South Africa:
- Diffuse Large B-Cell Lymphoma (DLBCL): Most common NHL; aggressive; treated with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone).
- Follicular Lymphoma: Indolent (slow-growing); often watch-and-wait initially; rituximab-based treatment when treatment becomes necessary.
- Mantle Cell Lymphoma: Aggressive; intensive chemotherapy required.
- Burkitt Lymphoma: Highly aggressive; requires urgent, intensive chemotherapy; common in HIV-positive SA patients.
- T-cell lymphomas: Less common; different treatment pathways.
HIV-associated lymphoma: South Africa's HIV epidemic creates a disproportionate burden of HIV-associated NHL, especially DLBCL and Burkitt lymphoma. These presentations are more common in SA than in low-HIV-prevalence countries and may present at an advanced stage.
How Common Is Lymphoma in South Africa?
The National Cancer Registry consistently places NHL among the top 10 cancers in South Africa. HIV-driven lymphoma is a significant contributor. Hodgkin lymphoma, while less common than NHL, is notably more common in young adults — including university-age South Africans — and carries a strongly positive prognosis with appropriate treatment.
Is Lymphoma a PMB Condition?
Yes. Both Hodgkin and Non-Hodgkin lymphoma are covered under the Prescribed Minimum Benefits as Level 1 oncological conditions. All registered schemes must fund:
- Diagnosis: Lymph node biopsy (excisional biopsy preferred; core-needle biopsy for less accessible nodes), pathology, immunohistochemistry, flow cytometry.
- Staging: CT of chest/abdomen/pelvis; PET/CT (gold standard); bone marrow biopsy for certain subtypes.
- Standard chemotherapy: ABVD for HL; CHOP for aggressive NHL.
- Radiation therapy: Involved-site radiation therapy (ISRT) for limited-stage HL and certain NHL subtypes.
Rituximab (anti-CD20 monoclonal antibody): Rituximab is a critical medicine for B-cell NHL treatment. It is the R in R-CHOP, R-CVP, R-DHAP, and other B-cell NHL regimens. It is not technically the PMB minimum treatment for all NHL subtypes under older DTP lists, but most SA schemes fund rituximab as part of the standard treatment for CD20-positive B-cell NHL — the SANHUG (South African National Haematology User Group) guidelines support its routine use.
Check with your scheme whether R-CHOP (rituximab-containing) is funded as PMB — if your scheme classifies CHOP (without rituximab) as the PMB minimum and requires exceptional-needs authorisation for rituximab, you need to apply for that authorisation promptly. Most schemes do fund rituximab for DLBCL; the gap arises more commonly for less common subtypes or second-line regimens.
How Does Medical Aid Cover Lymphoma?
| Treatment | PMB Status | Notes |
|---|---|---|
| Diagnostic biopsy + immunohistochemistry | Yes — PMB | Including HIV-associated lymphoma |
| Staging CT and PET/CT | Yes — PMB | |
| Bone marrow biopsy (staging) | Yes — PMB | |
| ABVD chemotherapy (Hodgkin) | Yes — PMB minimum standard | |
| R-CHOP (DLBCL and other CD20+ NHL) | Generally yes | Rituximab component confirm with scheme |
| ISRT (involved-site radiation) | Yes — PMB | For limited-stage HL |
| Second-line: R-DHAP, R-GDP, R-ICE | Exceptional needs in many schemes | Salvage protocols for relapsed disease |
| Polatuzumab vedotin (pola-R-CHP) | No — exceptional needs | Newer regimen for DLBCL |
| CAR-T cell therapy (relapsed DLBCL) | Exceptional needs / usually not funded | Very high cost; emerging access |
| Autologous stem cell transplant (ASCT) | PMB for qualifying patients | Consolidation after first-line response in high-risk DLBCL |
| Pembrolizumab (relapsed HL) | Exceptional needs | PD-1 inhibitor for relapsed/refractory HL |
Day-to-Day Costs: What to Budget For
Hodgkin Lymphoma:
| Scenario | Estimated Annual Cost |
|---|---|
| Limited-stage HL, ABVD × 4 cycles + radiation | R100,000 – R200,000 |
| Advanced-stage HL, ABVD × 6–8 cycles | R150,000 – R280,000 |
| Relapsed HL, pembrolizumab (exceptional needs) | R450,000 – R750,000 |
Non-Hodgkin Lymphoma (DLBCL):
| Scenario | Estimated Annual Cost |
|---|---|
| R-CHOP × 6 cycles (PMB) | R180,000 – R350,000 |
| Relapsed/refractory, second-line R-DHAP + ASCT | R350,000 – R600,000 |
| CAR-T cell therapy (if accessed) | R1,500,000 – R2,500,000+ [NEEDS VERIFICATION] |
Rituximab alone accounts for R15,000–R25,000 per cycle — a significant cost component in R-CHOP therapy.
Gap Cover Relevance
Gap cover is relevant for lymphoma treatment: - Haematologist / medical oncologist: Infusion fees per cycle attract shortfalls (R2,000–R8,000 per visit above scheme tariff). - Surgical oncologist: Excisional lymph node biopsy shortfalls. - Radiologist: PET/CT interpretation. - Radiation oncologist: ISRT for HL.
For DLBCL treated with 6 cycles of R-CHOP, specialist shortfalls across the treatment course can reach R60,000–R120,000 — within the gap OPL of approximately R220,000/year.
Key Questions to Ask Your Scheme
- Is rituximab funded as part of the PMB minimum treatment for my specific NHL subtype? Confirm in writing before your first cycle.
- Is PET/CT staging funded as PMB? PET/CT is superior to CT alone for lymphoma staging; funding varies.
- What is my oncology sub-limit? For ASCT or second-line treatment, sub-limit adequacy is critical.
- Is there a haematologist in my DSP network? Lymphoma is primarily treated by haematologists — confirm your treating doctor is scheme-recognised.
- Is there a facility in my network that performs autologous stem cell transplants? ASCT is only available at certain tertiary centres; network access must be confirmed in advance.
Talk to Eldon
R-CHOP, ASCT, and second-line lymphoma treatment push costs well above most standard plan sub-limits. AURA analyses oncology sub-limits, rituximab funding track records, and transplant access across 112 plans.
See which plans pay for lymphoma cover →